 Paper Publish Year,DOI,Carbohydrate/Protein Mimetic,Category ,Mimic of which Protein/Carbohydrate,Name of the Mimetic,Functions,Activity
2005,https://doi.org/10.1016/j.bmc.2005.06.059,Carbohydrate,,"Neu5Ac2en, which is a sialic acid derivative","β-O-glycosides of 4,5-unsaturated 2-acetamido-D-glucuronic acid","The function of β-O-glycosides of 4,5-unsaturated 2-acetamido-D-glucuronic acid is to act as mimetics and inhibitors of influenza virus sialidase",Mucopolysaccharidoses/Cancer: Disrupts glycosaminoglycan pathways
2006,https://doi.org/10.1016/j.tet.2006.05.080,Carbohydrate,glycosidases,glucose,1-cyano-2-phthalimidederivative,"1-Cyano-2-phthalimidederivatives are versatile compounds with a wide range of applications. They are primarily used as intermediates in organic synthesis, particularly in the preparation of various pharmaceuticals, agrochemicals, and dyes2. These derivatives exhibit significant biological activities, including anticancer, antibacterial, anti-inflammatory, and antifungal properties",Cancer Phthalimide derivatives like thalidomide and lenalidomide are used for multiple myeloma and autoimmune diseases
2006,https://doi.org/10.2174/138620706778249703,Carbohydrate,glycosidases,aglycon moiety,Tetrahydropyridoimidazole,"Tetrahydropyridoimidazole is a heterocyclic scaffold with diverse pharmacological functions, primarily in anticancer therapy, antimicrobial action, and ion channel modulation. Its biological activity stems from structural interactions with key cellular targets, modulated by substituents and stereochemistry.",Cancer: Targets EGFR mutants in non-small cell lung cancer (NSCLC)
2006,https://doi.org/10.1080/07328300600733020,Carbohydrate,glycoproteins,cyclic peptide cRGDFV,"vitronectins, avb3",a class of extracellular proteins that facilitate cell-cell recognition,"Cancer/Angiogenesis: Inhibitors (e.g., cilengitide) target tumor vasculature and metastasis"
2006,https://doi.org/10.1021/jo051989g,Carbohydrate,carbasugar,pyranose,"cyclooctane-1,2,3-triols",Glycosidase inhibitors,Explored as intermediates for glycoconjugates with potential antiviral/anticancer activity.
2006,https://doi.org/10.1016/j.tet.2006.05.080,Carbohydrate,Miscellaneous,D- glucose,b(1/6)-amide-linked oligomer,"The ( \beta (1/6) )-amide-linked oligomer is part of a new class of carbohydrate mimetics that are resistant to glycosidases. These oligomers have been investigated for their biological activities, such as anti-HIV activity and inhibition of sialyl Lewis x-mediated cell adhesion. The O-sulfated oligomers effectively inhibited HIV infection, sialyl Lewis x-mediated cell adhesion, and heparanase activity in a linkage-specific manner. Therefore, these molecules have potential applications as drugs that block protein–protein interactions and inhibit enzyme catalysis","Cancer Immunotherapy:(1→6)-β-glucose-branched poly-amido-saccharides (PASs) mimic β-glucans, stimulating macrophage polarization and enhancing antitumor immunity."
2006,https://doi.org/10.1016/j.tet.2006.05.080,Carbohydrate,glycosides,O-glycoside,S-glycosides,"S-Glycosides serve as robust tools in glycan synthesis and enzyme inhibition studies, leveraging their chemical stability and stereochemical control. While therapeutic applications are emerging, their resistance to degradation positions them as promising candidates for drug development and targeted delivery systems.","Cancer: Compound S-2 (β-D-xylopyranosyl derivative) showed moderate cytotoxicity against lung carcinoma (A-549 cells, IC₅₀ = 74 µM) by inducing apoptosis"
2007,https://doi.org/10.1039/B700034K,Carbohydrate,glycosaminoglycan,heparin,PI88,"under phase II clinical trials to treat herpes simplex viral infections,",Hepatocellular carcinoma (Phase III trials)
2007,https://doi.org/10.1093/glycob/cwm020,Carbohydrate,Polymer mimetic,GM3,GM3-p (GM3 mimetic polymer),Inhibits NIH3T3 cell proliferation,Potential use in metastatic cancers
2007,https://doi.org/10.1093/glycob/cwm020,Carbohydrate,Polymer mimetic,LacCer,LacCer-p (LacCer mimetic polymer),"Lactosylceramide mimetic polymer (LacCer-p) is a synthetic analog designed to replicate the structure of natural lactosylceramide (LacCer), a glycosphingolipid involved in membrane organization and signaling.",Potential use in metastatic cancers
2007,https://doi.org/10.2174/156802607779318325,Protein,cyclic peptide,extracellular matrix proteins that contain the Arg-Gly-Asp (RGD) sequence,c(RGDfV),Integrin antagonist : blocks integrin αVβ3 receptor binding,Inhibits angiogenesis : prevents tumor-induced blood vessel formation
2007,https://doi.org/10.2174/156802607779318325,Protein,cyclic peptide,Disintegrins,ACDCRGDCFCG,acts as an integrin antagonist by blocking the binding of natural ligands to integrin receptors like αVβ3 and αIIbβ3.,"It inhibits cell adhesion and migration, disrupting processes such as angiogenesis and tumor progression."
2007,https://doi.org/10.2174/156802607779318325,Protein,peptide,clic pentapeptide,diketopiperazine (DKP),Mimics peptide structures to support functional side chains.,Acts as an antagonist (specifically for CXCR4).
2007,https://doi.org/10.1039/b710425a,Protein,Synthetic backbone scaffold,α-helices peptides,Terphenyl scaffold,Designed to project sidechain functionality similar to that found in α-helices.,Used as inhibitors of protein–protein interactions
2007,https://doi.org/10.1039/b710425a,Protein,Peptide mimetic,Respiratory syncytial virus (RSV) protein,Cyclic pentapeptide scaffold,Mimics the α-turns of the RSV protein.,"Inhibits fusion of viral and cell membranes, preventing viral entry into cells."
2007,https://doi.org/10.1039/b710425a,Protein,Peptide mimetic,α-helices peptides,Hydrazone-linked peptides,To stabilize α-helical structures by replacing the N-terminal i and i + 4 hydrogen bond with a covalent link,Forms well-defined short α-helices with minimal perturbations to molecular recognition surfaces.
2007,https://doi.org/10.1039/b710425a,Protein,Peptide mimetic,α-helices peptides,Carbon–Carbon Linked Peptides,Introduces a carbon–carbon bond to stabilize the helical structure.,"Results in well-defined short α-helices from sequences that do not spontaneously form helices, with minimal perturbations to their molecular recognition surfaces"
2007,https://doi.org/10.1152/ajpcell.00097.2007,Protein,Connexin mimetic peptide,Cx43,43Gap27,Inhibits gap junction channel formation,No acute effect but moderate long-term attenuation of membrane conductance
2007,https://doi.org/10.1152/ajpcell.00097.2007,Protein,Pannexin mimetic peptide,Pannexin-1,10Panx1,Blocks pannexin-1 channel activity,Inhibits pannexin-1 channels; used to study ATP release and intercellular calcium wave propagation
2007,https://doi.org/10.1002/anie.200700657,Protein,α-helix mimetic,Bak BH3 domain,"2,3’,3’’-trisubstituted terphenyls","Mimics i, i+4, and i+7 residues of an α-helix","Inhibits protein–helix interactions, such as Bcl-xL/Bak and MDM2/p53"
2007,https://doi.org/10.4161/auto.4237,Protein,BH3 mimetic,BH3,ABT737,"Competitively inhibits the interaction between Beclin 1 and Bcl-2/Bcl-XL, which stimulates autophagy","ABT737 disrupts the inhibitory complex between Beclin 1 and Bcl-2/Bcl-XL, thus promoting autophagy by liberating Beclin 1 from its inhibition"
2007,https://doi.org/10.1158/0008-5472.CAN-07-5173,Protein,Smac mimetic compound,Smac,LBW242,"argets inhibitor of apoptosis proteins (IAPs) such as XIAP and cIAP1, leading to the induction of apoptosis in cancer cells","induces apoptosis in cancer cells by activating caspase-8, increasing TNFa expression, and overcoming drug resistance."
2007,https://doi.org/10.1002/pbc.21433,Protein,small molecule,BH3,ABT-263,limited single agent in vivo activity against the PPTP’s solid tumor panels but showed significant activity against xenografts in the ALL panel,"inhibits the antiapoptotic proteins Bcl-2, Bcl-xL and Bcl-w, demonstrated in vitro activity against a range of cell lines, with the
ALL cell lines showing the greatest sensitivity"
2007,https://doi.org/10.1002/pbc.21433,Protein,small molecule,BH3,ABT-737,"exhibits single-agent preclinical activity against lymphoma, small-cell lung carcinoma, and chronic lymphocytic leukemia and displays synergistic cytotoxicity with chemotherapeutics and radiation.",Bcl-2 inhibitor
2007,https://doi.org/10.1371/journal.pmed.0040316,Protein,small molecule,BH3,ABT-737,"its addition significantly enhances killing of NSCLC cells by
the EGFR tyrosine kinase inhibitor gefitinib",EGFR tyrosine kinase inhibitor gefitinib.
2008,https://doi.org/10.1016/j.tetlet.2008.05.040,Carbohydrate,NA,a-L-rhamnopyranose,"3,5-di-O-benzyl-D-pinitol","Mimics α-L-rhamnopyranose unit in bioactive saccharides, interacts with dendritic cells, potential use in stable mimic of capsular polysaccharide in Streptococcus pneumoniae",Inhibits breast and prostate cancer growth via NF-κB/MMP-9 and FAK/c-Src pathways
2008,https://doi.org/10.1016/j.bmc.2007.11.036,Carbohydrate,Iminosugar,α-D-mannose,Swainsonine,Glycosidase inhibitor,"Cancer Therapy:Swainsonine inhibits α-mannosidase II, disrupting N-glycan processing and suppressing tumor metastasis"
2008,https://doi.org/10.1042/BST0361414,Protein,proteomimetic inhibitors,Bak/Bim BH3 Domains,"Trisubstituted 3,2,2-terphenyl derivatives",Mimics α-helical structure to disrupt protein–protein interactions,"central aryl ring adopts a staggered conformation, effectively mimicking the position and projection of i, i + 3 or i + 4 and i + 7 residues on one face of the helix"
2008,https://doi.org/10.1042/BST0361414,Protein,proteomimetic inhibitors,smMLCK (smooth muscle myosin light-chain kinase),The terphenyl scaffold,Disrupts protein–protein interactions,binds to calmodulin using an α-helical domain
2008,https://doi.org/10.2174/187152708783885174,Protein,Peptidomimetic,pharmacophores of mAb 5C3 and NGF peptide analogues,C59,"C59 (Wnt-C59) is a small-molecule inhibitor of the Wnt signaling pathway. It functions by targeting Porcupine (PORCN), a membrane-bound O-acyltransferase essential for the palmitoylation and secretion of Wnt proteins, thereby preventing both canonical and non-canonical Wnt-mediated signaling.",Lacked neurotrophic effects
2008,https://doi.org/10.1158/1535-7163.MCT-08-0285,Protein,Small molecule mimetic,BH3,ABT-737,restores sensitivity of Bcl-2-overexpressing cells but not Mcl-1- overexpressing cells to apoptotic stimuli,binds Bcl-2 and Bcl-xL but not Mcl-1
2008,https://doi.org/10.1158/1535-7163.MCT-08-0285,Protein,phosphomimetic,phosphorylated state of Mcl-1,phosphomimetic Mcl-1 protein (S64E),"use of the S64E protein is biologically relevant, as mouse and rat Mcl-1 wild-type proteins contain a glutamic acid at this position",Noxa binds much more strongly to S64E Mcl-1 than the unphosphorylatable S64A protein
2009,https://doi.org/10.1039/B914356D,Carbohydrate,Miscellaneous,mannose,"1,2-oxazines syn-8 ( Bicyclic ketones 15)","Bicyclic ketone 15 serves as an ideal starting point for the preparation of suitable substrates for the copper-catalyzed 1,3-dipolar cycloaddition of azides with alkynes, which is a key step in the synthesis of oligosaccharide mimetics","Cancer: Serve as intermediates for polyoxygenated oxepanes, which target cancer cell proliferation"
2009,https://doi.org/10.1039/B914356D,Carbohydrate,Miscellaneous,glucosamine,"1,2-oxazines anti syn-8 ( Bicyclic ketones 17)","The 1,2-oxazines syn-8, when exposed to Lewis acids, can be transformed into either bicyclic ketones 15 or tricyclic compounds 16, depending on the nature of the 4-alkoxy group [1]. Additionally, the 1,2-oxazines syn-8 and anti-8 can undergo Lewis acid-promoted rearrangements leading to bi- and tricyclic products","Cancer: Serve as intermediates for polyoxygenated oxepanes, which target cancer cell proliferation"
2009,https://doi.org/10.1021/ja810025g,Protein,α-helix mimetic,Bak bh3 domain,Hamilton Terphenyl Motif,"mimics the structural and recognition features of an R-helix, facilitating the design of various derivatives.","effectively present side chains at the i, i + 4, and i + 7 positions, which are critical for mimicking the natural interactions of R-helices in proteins"
2009,https://doi.org/10.1161/ATVBAHA.109.187518,Protein,Peptide Mimetic,ApoA-I,L-4F,ability to resist enzymatic degradation,"inhibit atherosclerotic lesions , binds niclosamide forming a very tight association that protects the peptide from trypsin digestion allowing L-4F absorption and biological activity after oral administration"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,4–8 N-terminal residues of Smac,targets MCF-7 breast cancer cells,"combines with Paclitaxel, etoposide, SN-38,
or doxorubicin"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,4 or 7 N-terminal residues of Smac,targets  Human acute leukemia Jurkat T cells,"combines with Epothilone B derivative
(BMS 247550) or Apo-2L/TRAIL"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,7 N-terminal residues of Smac,targets  L428 and L540 human Hodgkin lymphoma cells,combines with Granzyme B
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,7 N-terminal residues of Smac with antenopedia sequence,targets Caki-1 renal carcinoma cells,combines with None or cisplatin
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,7 N-terminal residues of Smac conjugated to 8 arginine residues,"targets Suit-2, CFPAC-1, Panc1, and BxPC-3 pancreatic cancer cells (a) H460 non-small-cell lung cancer, (b) H460 xenograft mouse model","combines with (a) Cisplatin or taxol, (b) cisplatin"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,7 N-terminal residues of Smac conjugated to the protein transduction domain of TAT protein,"targets (a) SHEP/Bcl-2 neuroblastoma, SH-SY5Y
neuroblastoma, Mel-HO melanoma, Panc1
pancreatic carcinoma, (b) U87 MG human
malignant glioma xenograft mouse model","combines with (a) TRAIL or doxorubicin, (b) TRAIL"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Peptides,Smac,Polyvalent naı¨ve phage-derived peptide sequences based on N-terminus of Smac with natural and unnatural amino acid substitutions,targets ML-IAP-overexpressing melanoma cell lines,"The polyvalent naïve phage-derived peptide sequences based on the N-terminus of Smac (Second Mitochondrial Activator of Caspases) with natural and unnatural amino acid substitutions are designed to antagonize Inhibitor of Apoptosis Proteins (IAPs), such as XIAP, to restore caspase-mediated apoptosis in cancer cells"
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Polynucleotides,Smac,Flag-C-tagged mature Smac pcDNA3.1,targets K562 and CEM human leukaemic cells,combines with Ultraviolet light or TRAIL
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Polynucleotides,Smac,Flag-C-tagged full-length Smac,targets NC65 and Caki-1 renal carcinoma cells,combines with TRAIL or cisplatin
2009,https://doi.org/10.1097/CAD.0b013e32832ced78,Protein,Polynucleotides,Smac,pcDNA3.1,targets Human acute leukemia Jurkat T cells,combines with Epothilone B derivative (BMS 247550) or Apo-2L/TRAIL
2009,https://doi.org/10.1016/j.biomaterials.2008.09.040,Protein,homopolymers or copolymers,Elastin,VPGVG,Mimics the natural flexibility and biocompatibility of elastin for implant-related applications,Does not induce significant inflammatory or allergic reactions; not recognized as an antigenic epitope of elastin
2009,https://doi.org/10.1007/s11883-009-0008-8,Protein,peptide,Apolipoprotein A-I (apoA-I),4F Peptides,Increases formation of pre-β HDL; enhances cholesterol efflux; reduces lipoprotein oxidation; improves antioxidants and vascular repair; reduces renal inflammation,"Improves vasodilation, oxidative stress, myocardial inflammation, and angiogenic potential in various models; reduces adiposity and improves insulin sensitivity in obese mice; improves HDL inflammatory properties in humans with coronary heart disease"
2009,https://doi.org/10.1002/bip.21164,Protein,Cyclic ligand-mimetic,Arg-Gly-Asp (RGD) peptide,Cilengitide,"Binds to and inhibits avβ3 and avβ5 integrins, inhibiting endothelial interactions and angiogenesis",Currently in clinical trials for the treatment of glioblastoma
2009,https://doi.org/10.1002/ejoc.200900599,Protein,β-Substituted amino acids,"tryptophan residues in α-helical domains of proteins,",β-MeTrp,an increased biological stability of the modified peptides,comparably higher activity
2009,https://doi.org/10.1002/ejoc.200900599,Protein,side-chain-modified amino acids,tryptophan (Trp) or phenylalanine (Phe),2-naphthylalanine,This compound in combination with other unnatural amino acids can be used for the synthesis of Gonadotropin-releasing hormone (GnRH) antagonists,show a high affinity to the receptor
2009,https://doi.org/10.1002/ejoc.200900599,Protein,naturally occurring protease inhibitor,NA,OF4949-III,"exhibits immunopotentiating activity and were confirmed to have antitumor activity, without showing toxicity",competitive inhibitor for aminopeptidase B
2009,https://doi.org/10.1158/1535-7163.MCT-09-0493,Protein,small-molecule,BH3,HA14-1,promising anticancer agent,able to inhibit the activity of antiapoptotic Bcl-2 family proteins
2010,https://doi.org/10.1517/17460441.2010.497811,Carbohydrate,iminosugar,mannose,swainsonine,anticancer drug with the potential of treating glioma [120] and gastric carcinoma,Lung cancer: Inhibits A549 cell growth in vitro and reduces xenograft tumor volume in vivo
2010,https://doi.org/10.1016/B978-0-12-374546-0.00047-X,Carbohydrate,Iminosugars,mannose,Swainsonine,Swainsonine functions as a glycosidase inhibitor,"Cancer:Inhibits α-mannosidase II, disrupting N-glycan processing and suppressing tumor metastasis in preclinical models"
2010,https://doi.org/10.4155/fmc.10.8,Carbohydrate,inhibitor,glucosidase,Swainsonine,used as an anticancer drug with potential for treating glicoma and stomach cancer,"Cancer:Inhibits α-mannosidase II, disrupting N-glycan processing and suppressing tumor metastasis in preclinical models"
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Protein,Synthetic receptor,"
Mutant p53 (p53-R337H)",amphiphilic calixarenes embedded in chromatic phospholipid/polydiacetylene (PDA) vesicles,Induces changes in vesicle absorption spectra,Multivalent interactions
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Protein,Porphyrin-based receptor,"Metaloproteins (e.g., cytochrome c, myoglobin)",TCPP-based receptors,Binding to protein surfaces,Fluorescence quenching upon binding
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Protein,Nanoparticle-based receptor,TAT (HIV transactivator of transcription),Gold nanoparticles conjugated to b-galactosidase,Nanoparticle-based receptor,Disruption of enzyme-NP interaction
2010,https://doi.org/10.1016/j.cbpa.2010.07.017,Protein,Nucleic acid-based receptor,red fluorescent protein,DNA G-quadruplexes,Monitoring changes in fluorescence,Changes in emission of fluorophores
2010,https://doi.org/10.4155/fmc.10.259,Protein,Venom-derived peptide,NA,Chlorotoxin,capable of blocking chloride channels,"binds exclusively to glioma cells, opening the possibility for treatment and diagnosis of particular cancers."
2010,https://doi.org/10.2174/138920310791330622,Protein,Peptide,β-Strand Motifs (PCSK9/LDLR Interaction),Trisubstituted imidazole scaffolds,inhibition of Bcl proteinprotein interactions,disrupt the interaction of Bcl-w and Bak-BH3
2010,https://doi.org/10.2174/138920310791330622,Protein,Helical mimetic,Bak BH3 domain,Trispyridylamide scaffold,"antagonist of Bcl-xL,",bifurcated hydrogen-bonding network as well as the minimization of destabilizing conformations allows for the observed geometry
2010,https://doi.org/10.2174/138920310791330622,Protein,Helical mimetic,α-helical BH3 domain of the pro-apoptotic protein Bak,Terephthalamide scaffold,antagonist of Bcl-xL,stablilized by an intramolecular hydrogen bond
2010,https://doi.org/10.2174/138920310791330622,Protein,Small molecule mimetic,α-helical BH3 domain of the pro-apoptotic protein Bak,"1,4-benzodiazepine-2,5-dione derivatives (BZD)",mimics the critical helical peptide side chains of a known peptide substrate of HDM2,bind to HDM2
2010,https://doi.org/10.2174/138920310791330622,Protein,Small molecule mimetic,CDK6,3-hydroxymethylindole,block ligand binding to MAGI3-PDZ2,to block the interaction of PTEN-MAGI3-PDZ2 was investigated via fluorescence polarization
2010,https://doi.org/10.2174/138920310791330622,Protein,alpha-helix mimetics,hydrophobic helix D region of CD81,Bisimidazole scaffolds,intramolecular hydrogen bond stabilizes the amide group substituents in a conformation which closely matches the side chain separations on one face of an -helix,utilized to disrupt the interaction of CD81 and HCV-E2.
2010,https://doi.org/10.1016/j.addr.2010.04.007,Protein,elastin-mimetic triblock copolymer,elastin,B9,Drug delivery,"Monodisperse size distribution, spherical shape"
2011,https://doi.org/10.1039/C1OB05583F,Carbohydrate,Mixed-Type Oligosaccharides,d-fructose,acyclic aminopolyols,"Acyclic aminopolyols function as carbohydrate mimetics used to enhance selectin binding properties. They are attached to gold colloids and sulfated to improve ligand-receptor interactions. These sulfated colloids exhibit strong selectin binding properties and no signs of cytotoxicity, serving as a valuable example of improved ligand-receptor interactions when presented multivalently","Diabetes, Viral Infections, Cancer: Synthesized via biocatalytic amination of sugars, these compounds act as carbohydrate mimetics for diabetes management, antiviral therapies, and antitumor agents"
2011,https://doi.org/10.1073/pnas.1105057108,Carbohydrate,peptide,Lewis A carbohydrate,"I-peptide, which is a 7-mer peptide","The function of I-peptide, which is a 7-mer peptide, is to inhibit sialyl Lewis X-dependent colonization by binding to a receptor distinct from E- or P-selectins. It was found to bind to a 15 kDa fragment of annexin 1 (Anxa1), which is a highly specific marker of the tumor vasculature surface","Cancer: Targets annexin 1 (Anxa1) on tumor vasculature for drug delivery. Conjugated to SN-38 (chemotherapy drug), it suppresses colon cancer (HCT116) growth in mice"
2011,https://sci-hub.se/10.1055/s-0030-1260139,Carbohydrate,imino sugar derivative,oligosaccharide,"2,6-functionalized pyranoid glycoaminoxy acid","The 2,6-functionalized pyranoid glycoaminoxy acid serves as a building block for the construction of novel 2,6-linked oligosaccharide mimetics. It is used for chemical ligations with various amines, carboxylic acids, or aldehydes through amide, oxime, or oxyamine bonds, respectively. This makes it a useful tool for the synthesis of oligosaccharide mimetics with potentially diverse practical application",Cancer: Used to synthesize oligosaccharide mimetics that inhibit tumor growth and metastasis
2011,https://doi.org/10.1134/S1068162011060100,Carbohydrate,Mixed-Type Oligosaccharides,heparinoids,Sulfated Phosphomannan PI88,"Sulfated phosphomannan PI88 functions as a heparanase inhibitor and an angiogenesis inhibitor. It blocks the action of heparanase, which is involved in cancer cell metastasis, and interacts with growth factors (FGF-1, FGF-2, VEGF) and their receptors (FGFR) to inhibit angiogenesis","Hepatocellular Carcinoma (HCC): Inhibits heparanase, reducing tumor growth and metastasis in clinical trials"
2011,https://doi.org/10.1134/S1068162011060100,Carbohydrate,Mixed-Type Oligosaccharides,heparinoids,sulfated hexasaccharide,"Sulfated hexasaccharides play diverse biological roles due to their structural and sulfation patterns. Neurodevelopment: Promote cerebellar Purkinje cell growth and neurite outgrowth by interacting with neurotrophic factors like pleiotrophin.Growth Factor Modulation: Mimic heparan sulfate to regulate fibroblast growth factor 2 (FGF-2) activity, influencing cell proliferation and disease pathways.Immune Regulation: Inhibit selectins (L-, E-, and P-selectins) to modulate inflammation, lymphocyte homing, and tumor metastasis.","Cancer Metastasis: Dual inhibition of heparanase and selectins, blocking tumor cell spread"
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,Protein,b-hairpin mimetics,LptD (outer membrane protein),Bcl-2,Targets outer membrane biogenesis,Inhibits LPS transport to the outer membrane
2011,https://doi.org/10.1016/j.cbpa.2011.02.015,Protein,CAMP Mimetics,Defensins,Oligomeric aryl ureas,Antimicrobial properties,mechanisms differ in effectiveness
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,HA14-1,"Targets leukemia, myeloma, glioblastoma, prostate cancer",Inhibits Bcl-2
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,BH3-Is,"Targets leukemia, prostate cancer, non-small cell lung cancer",Inhibits Bcl-XL
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,Antimycin A,Targets leukemia and cervical cancer,"Inhibits Bcl-2, Bcl-XL"
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,Gossypol,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,Apogossypol,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,TW-37,"Targets leukemia, lymphoma, glioblastoma, prostate cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,GX015-070,"Targets leukemia, lymphoma, myeloma, lung cancer","Inhibits Bcl-2, Bcl-XL, Mcl-1"
2011,https://doi.org/10.1016/j.drup.2007.08.002,Protein,small-molecule BH3 mimetics,BH3,ABT-737,"Targets leukemia, lymphoma, lung cancer, breast cancer","Inhibits Bcl-2, Bcl-XL, Bcl-w"
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4- phenylenebis(methylene))bis(1H-1,2,3-triazole-4,1- diyl))bis(phenylmethylene))bis(6-((S)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide)",Induces degradation of cIAP2,Fails to induce caspase-3 processing at 30 nM
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4-phenylenebis(ethane-2,1- diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2- (methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3- carboxamide)",Induces degradation of cIAP1/2,Limited effect on cIAP1 degradation at 30 nM
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4- phenylenebis(propane-3,1-diyl))bis(1H-1,2,3-triazole-4,1- diyl))bis(phenylmethylene))bis(6-((S)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide)",Induces degradation of cIAP1,Induces PARP cleavage and caspase-3 processing
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(1,4-phenylenebis(hexane-6,1-
diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2-
(methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-
carboxamide)",Induces degradation of cIAP1/2,Robust activity at low concentrations
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(S,3S,3′S,6S,6′S,10aS,10a′S)-N,N′-((1S,1′S)-(1,1′-(oxybis(pentane-5,1- diyl))bis(1H-1,2,3-triazole-4,1-diyl))bis(phenylmethylene))bis(6-((S)-2- (methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3- carboxamide)",Antagonist of IAPs,Completely inhibits tumor growth in MDA-MB-231 xenografts
2011,https://doi.org/10.1021/jm101651b,Protein,Bivalent,smac,"(3S,6S,10aS)-6-((R)-2-acetamido-3-(1H-indol-3-yl)propanamido)-N-((S)-(1-(4-(4- (4-(4-((S)-((3S,6S,10aS)-6-((R)-2-(methylamino)propanamido)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamido)(phenyl)methyl)-1H-1,2,3- triazol-1-yl)butyl)phenyl)butyl)-1H-1,2,3-triazol-4-yl)(phenyl)methyl)-5- oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide",Several times less potent than the most potent bivalent mimetics,"The compound (3S,6S,10aS)-6-((R)-2-acetamido-3-(1H-indol-3-yl)propanamido)-N-((S)-(1-(4-(4-(4-(4-((S)-((3S,6S,10aS)-6-((R)-2-(methylamino)propanamido)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamido)(phenyl)methyl)-1H-1,2,3-triazol-1-yl)butyl)phenyl)butyl)-1H-1,2,3-triazol-4-yl)(phenyl)methyl)-5-oxodecahydropyrrolo[1,2-a]azocine-3-carboxamide is a bivalent Smac mimetic designed to antagonize inhibitor of apoptosis proteins (IAPs) such as XIAP, cIAP1, and cIAP2. Its activity centers on restoring apoptosis in cancer cells by mimicking the AVPI tetrapeptide motif of the Smac protein, which naturally binds IAPs to neutralize their anti-apoptotic effects."
2011,https://doi.org/10.1038/onc.2011.104,Protein,Small molecule mimetic,BH3,ABT737,"induces autophagy by competitively disrupting the inhibitory interaction between the BH3 domain of Beclin 1 and the anti-apoptotic proteins Bcl-2 and Bcl-XL, thereby stimulating the Beclin 1-dependent allosteric activation of the pro-autophagic lipid kinase VPS34","caused the activating phosphorylation of AMP-dependent kinase (AMPK) and of the AMPK substrate acetyl CoA carboxylase, the activating phosphorylation of several subunits of the inhibitor of NF-jB (IjB) kinase (IKK) and the hyperphosphorylation of the IKK substrate IjB, inhibition of the activity of mammalian target of rapamycin (mTOR) and consequent dephosphorylation of the mTOR substrate S6 kinase. In addition, ABT737 treatment dephosphorylates (and hence likewise inhibits) p53, glycogen synthase kinase-3 and Akt"
2011,https://doi.org/10.1038/onc.2011.104,Protein,Small molecule mimetic,BH3,HA14-1,highly efficient in inducing autophagy including in U2OS and HeLa cells,"induced LC3 lipidation, p62 degradation and GFP-LC3 redistribution to autophagic dots in control and Bax/Bak/ double-knockout MEFs similarly"
2011,https://doi.org/10.1177/1947601911417177,Protein,small molecule,BH3,ABT-737,"Phases I and II: leukemia, lymphoma, myeloma, small cell lung cancer, cervical cancer, breast cancer","Binding to BCL-2 Members: Ki for BCL-2 = 1 nM
Ki for BCL-xL = 0.5 nM
Ki for BCL-w = 1 nM
Ki for MCL-1 = 550 nM"
2011,https://doi.org/10.1177/1947601911417177,Protein,small molecule,BH3,Apogossypol,Preclinical,". BCL-2 Family Inhibitor: Ki
 for BCL-2 = 35 nM
Ki
 for BCL-xL = 660 nM
Ki
 for MCL-1 = 25 nM"
2011,https://doi.org/10.1177/1947601911417177,Protein,small molecule,BH3,(–)Gossypol,"Phases I and II: chronic lymphocytic leukemia, non-Hodgkin lymphoma, glioblastoma, head and neck, prostate cancer, small cell lung cancer","bind BCL-2, BCL-xL, and MCL-1 although with affinities
that are much lower than of the BH3-only proteins to these
proteins, BCL-2 Family Inhibitor: Ki
 for BCL-2 = 320 nM
Ki
 for BCL-xL = 480 nM
Ki
 for MCL-1 = 180 nM"
2011,https://doi.org/10.1177/1947601911417177,Protein,small molecule,BH3,GX-15-070,"Phase I: leukemia, lymphoma, multiple myeloma, non–small cell lung cancer",". BCL-2 Family Inhibitor: Ki
 for BCL-2 = 220 nM
Ki
 for BCL-xL = 0.5 µM
Ki
 for MCL-1 = 0.5 µM"
2011,https://doi.org/10.1177/1947601911417177,Protein,small molecule,BH3,TW-37,"Phases I and II: chronic lymphocytic leukemia, non-Hodgkin lymphoma, glioblastoma, head and neck cancer, prostate cancer, small cell lung cancer",". BCL-2 Family Inhibitor: Ki
 for BCL-2 = 290 nM
Ki
 for MCL-1 = 260 nM"
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Carbohydrate,Glycomemitics,Heparan Sulphate,PI-88,"a highly sulfonated oligosaccharide that mimics heparan sulfate and has potent anti-angiogenic activity, currently in clinical trials","Inhibits heparanase activity and angiogenesis, showing potential as an anti-cancer and anti-metastatic agent."
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Carbohydrate,Glycomemitics,Heparan Sulphate,Small molecule fluoro-xylosides,"small molecules that mimic heparan sulfate and potently reduce tumor-associated angiogenesis by inhibiting HS biosynthesis in vitro, requiring cellular entry to be effective","Disrupts HS biosynthesis, leading to reduced tumor angiogenesis and potential anti-cancer applications."
2012,https://doi.org/10.1016/j.bmcl.2012.04.014,Carbohydrate,Glycomemitics,Heparan Sulphate,Polysulfonated small molecules,"these mimic heparin/heparan sulfate and act as inhibitors of angiogenesis, identified as promising in vitro tube formation assay inhibitors and can be easily synthesized","Prevents angiogenesis by inhibiting heparan sulfate interactions, making them potential therapeutic agents for cancer treatment."
2012,https://doi.org/10.1155/2012/740982,Carbohydrate,GD1α-mimetic peptide,GD1α (a ganglioside),GD1 α-mimetic peptides,"These peptides functionally mimic GD1α, which is an adhesion molecule involved in tumor metastasis.",GD1α-replica peptides suppress tumor metastasis.
2012,https://doi.org/10.1593/neo.111544,Carbohydrate,Carbohydrate-based galectin inhibitor,Galactoside-containing polysaccharide,Modified Citrus Pectin (MCP),"Inhibits galectin-3, blocking its antiapoptotic function and tumor cell clonogenic survival","Shown to inhibit experimental metastasis in various animal models, including melanoma and prostate carcinoma"
2012,https://doi.org/10.1593/neo.111544,Carbohydrate,Synthetic β-galactoside disaccharide/amino acid conjugate,Cancer-associated Thomsen-Friedenreich antigen (TF-Ag),Glycoamine Lactulose-L-leucine (Lac-L-Leu),"Binds and inhibits galectin-3, mimicking TF-Ag",Impedes metastasis-associated tumor cell adhesive interactions and inhibits the formation of early metastatic deposits in lungs and bones
2012,https://doi.org/10.1371/journal.pone.0035457,Carbohydrate,Carbohydrate mimetic peptide,GD2 ganglioside,Peptides mimicking GD2 ganglioside,"These peptides are designed to mimic the structure of GD2 ganglioside, which is a tumor-associated antigen.","They elicit immune responses, including cellular and humoral immunity, and can potentially be used in cancer immunotherapy"
2012,https://doi.org/10.1371/journal.pone.0035457,Carbohydrate,Carbohydrate mimetic peptide,GD3 ganglioside,Peptides mimicking GD3 ganglioside,"Similar to GD2 mimics, these peptides replicate the structure of GD3 ganglioside, facilitating recognition by specific antibodies.","They can induce anti-ganglioside immune responses, contributing to the development of therapeutic strategies against cancers expressing GD3"
2012,DOI: 10.2174/138955712803832753,Carbohydrate,Synthetic carbohydrate mimetic,GDP-fucose,GDP-hexanolamine,Inhibitors of fucosyltransferases,"Potential treatment for cancer and inflammatory diseases by inhibiting fucosylation processes involved in cell-cell recognition, cell adhesion, and signaling pathways"
2012,DOI: 10.2174/138955712803832753,Carbohydrate,Synthetic carbohydrate mimetic,Trisaccharide	,Azatrisaccharide containing a piperidine ring,Inhibitor of glycosyltransferases,Potential treatment for cancer and inflammatory diseases by inhibiting aberrant glycosylation processes
2012,DOI: 10.2174/138955712803832753,Carbohydrate,Synthetic carbohydrate mimetic,N-Ac-lactosamine,N-Ac-lactosamine mimetics,Inhibitor of glycosyltransferases,Potential treatment for cancer and inflammatory diseases by inhibiting aberrant glycosylation processes
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate,Carbohydrate-Mimetic Peptides,Non-reducing terminal galactose structure.,9-mer Peptides,Recognized by monoclonal antibodies directed to lacto-tetraosylceramide and neolactotetraosylceramide. Bind to Ricinus lectin and inhibit Jack bean β-galactosidase activity toward neolactotetraosylceramide,Potential applications in cancer therapy and treatment of infectious diseases by mimicking carbohydrate antigens and modulating galactose-mediated cellular processes
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate,Carbohydrate-Mimetic Peptides,Lewis Y antigen.,PWLY Peptide,Induces an immune response against the Lewis Y antigen.,"Can elicit an immune response in rabbits and mice, demonstrating its potential as a vaccine component"
2012,https://doi.org/10.1093/glycob/cwr140,Carbohydrate,Carbohydrate-Mimetic Peptides,Sialyl Lewis X (a carbohydrate ligand).,I-Peptide (IELLQAR),Inhibits the binding of sialyl Lewis X to E-selectin.,"Inhibits lung colonization of melanoma cells, potentially useful for cancer metastasis prevention. May also have applications in treating inflammatory conditions and modulating immune responses."
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,BH3 mimetic,BH3 proteins( BAD),ABT-737,Induces proapoptotic and anti-tumour effects,"Binds to BCL-2, BCL-XL, and BCL-W proteins and disrupt interaction with BECLIN 1 causing autophagy. Induce BX/BAK dependent apoptosis"
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,Inhibitor molecule,BH3 proteins,BIM-SAHB,"Restricts mitochondria ,activates caspases-3 and 7 , reactivates cell death in leukaemia and lymphoma cells which are resistant to ABT-737","Binds with BCL-XL, BCL-W, MCL-1 and A-1 while blocks the sequestration of BAX by BCL-XL and BAK by MCL-1 and instead triggers direct release of BAX/BAK dependent mitochondrial cytochrome C"
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,BAD-like BH3 mimetic,BH3 proteins(BAD),ABT-263(Navitoclax),Induces proapoptotic and anti-tumour effects (oral derivative of ABT-737),"Binds to BCL-2, BCL-XL, and BCL-W proteins and disrupt interaction with BECLIN 1 causing autophagy. Induce BX/BAK dependent apoptosis"
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,Inhibitor molecule,BH3 proteins,MIM 1,Inhibits MCL-1 and is hence used in malignant cells with MCL-1,Targets hydrophobic pockets of MCL-1 and induces BAX/BAK apoptosis in MCL-1 dependent but not BCL-XL dependent leukaemia cells
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,Activator molecule,BH3 proteins,BMP 7,Induces apoptosis by directly activation of BAX in BAK deficient cells,Selectively interacts with BAX triggering sites while not interacting with BH3 binding groove of BCL-2 proteins
2012,https://doi.org/10.1158/1535-7163.MCT-13-0058,Protein,Inhibitor molecule,BH3 proteins(inhibit BCL-2),ABT-199,Induces apoptosis of haematological tumour lines while sparing platelet cells( derivative of ABT-263),Specifically targets BCL-2 and not BCL-XL hence avoiding thrombocytopenia at the same time induce BX/BAK dependent apoptosis
2012,https://doi.org/10.1016/j.ddtec.2011.07.006,Protein,PEM scaffold,Polyphemusin II,POL3026,CXCR4 antagonist,harvests peripheral blood HSCs by disrupting the SDF-1/CXCR4 interaction
2012,https://doi.org/10.1016/j.ddtec.2011.07.006,Protein,PEM scaffold,Polyphemusin II,POL5551,CXCR4 antagonist,POL5551 as a CXCR4 antagonist in acute lymphoblastic leukemia
2012,https://doi.org/10.1016/j.ddtec.2011.07.006,Protein,PEM scaffold,Polyphemusin II,POL6326,CXCR4 antagonist,POL6326 (balixafortide) as a CXCR4 antagonist in clinical trials for breast cancer
2013,https://doi.org/10.1021/bc400246z,Protein,antibody mimetic (FPF),IgG,Anti-VEGF,inhibits angiogenesis,provides bivalent binding properties similar to IgG antibodies
2013,https://doi.org/10.1021/bc400246z,Protein,antibody mimetic (FPF),IgG,Anti-Her2,inhibits angiogenesis,provides bivalent binding properties similar to IgG antibodies
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,MEK2 (N-terminal region),Antp-MEK2,Inhibits ERK2 activation,Potential anti-cancer activity by inhibiting cell proliferation signaling
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,MEK2 (N-terminal region),Tat-MEK2,Inhibits ERK2 activation,Potential anti-cancer activity by inhibiting cell proliferation signaling
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,p14ARF (N-terminal),(D-Arg)9-ARF26-44,Promotes apoptosis,Potential anti-cancer activity by inducing programmed cell death
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,c-Myc (C-terminal helix 1),"Int-Hi-S6A, F8A",Inhibits proliferation and promotes apoptosis,Anti-cancer activity by inhibiting cell growth and inducing cell death
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,p53 (C-terminal region),RI-TAT p53C’,Promotes apoptosis,Activates p53 in cancer cells
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Smac/Diablo (N-terminal),SmacDiablo Penetratin peptide,Promotes apoptosis,Chemotherapy induces apoptosis
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Shepherdin,Penetratin- Shepherdin79–83,Selective apoptosis of acute myeloid leukaemia cells,Potential treatment for acute myeloid leukemia
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,ELK1 (DEF docking site),Tat-DEF-Elk1,Regulates cytonuclear trafficking of ELK1,Potential modulator of gene expression in various diseases
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,B-Raf (Dimer interface),Tat-DI2,Inhibits Raf dimerization and proliferation of NSCLC cell lines,Potential treatment for non-small cell lung cancer
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,S100C/A11 (N-terminal),TAT-MAK19,Promotes apoptosis,Potential anti-cancer activity by inducing programmed cell death
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,p21(WAF1/CIP1),Tat48–60-P10,Promotes apoptosis,Potential anti-cancer activity by inducing programmed cell death
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Cyt c (77–101),Nup153-Cyt c,Potent Apoptogenic analogue of Cyt c77–101,Potential anti-cancer activity by inducing apoptosis
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Mastoparan analogue,Mitoparan,Promotes apoptosis and mitochriotoxic,Potential anti-cancer activity by targeting mitochondria
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,Cytochrome c,Cyt c77–101,Promotes apoptosis,Potential anti-cancer activity by inducing programmed cell death
2013,https://doi.org/10.1002/biot.201200335,Protein,Bioportide,p14ARF (N-terminal),ARF (1–22),Promotes apoptosis in cancer cells,Potential anti-cancer activity by inducing programmed cell death
2013,https://doi.org/10.1073/pnas.1312473110,Protein,ligand of CH1,HIF-1α C-TAD,HBS1,reduces tumour volume,"disrupts the HIF-1α/p300-CH1 complex in vitro, down-regulates hypoxia-inducible gene expression, and reduces VEGF protein levels in hypoxic cells"
2013,https://doi.org/10.1016/j.bmc.2012.09.053,Protein,N-alkylated oligobenzamide,α-Helix,"4,4-dicarboxamide",targets protein-protein interactions,"Potential inhibitor of Bcl-xL/Bak interaction, which may induce apoptosis in cancer cells"
2013,https://doi.org/10.1016/j.bmc.2012.09.053,Protein,N-alkylated oligobenzamide,α-Helix,terephthalamide,targets protein-protein interactions,"Disrupts Bcl-xL/Bak complex formation, potentially inducing apoptosis in cancer cells"
2013,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392204/,Protein,phosphoserine mimetics,14-3-3 binding motifs,"Oxirane ring opening by α,α-difluoromethylenephosphonate anion to furnish γ-hydroxy-α,α-difluoromethylenephosphonates",14-3-3 Protein Inhibitory Activity,"targets including the tumor suppressor p53, Raf family kinases, FOXO transcription factors, the proapoptotic protein BAD, and Cdc25 phosphatases through these recognition sequences. Upon binding, 14-3-3 acts as an adaptor, leading to changes in enzymatic activity or subcellular localization .These characteristics make the 14-3-3 family an interesting target for cancer therapeutics"
2013,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392204/,Protein,phosphoserine mimetics,14-3-3 binding motifs,WW domains,14-3-3 Protein Inhibitory Activity,"targets including the tumor suppressor p53, Raf family kinases, FOXO transcription factors, the proapoptotic protein BAD, and Cdc25 phosphatases through these recognition sequences. Upon binding, 14-3-3 acts as an adaptor, leading to changes in enzymatic activity or subcellular localization .These characteristics make the 14-3-3 family an interesting target for cancer therapeutics"
2013,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392204/,Protein,phosphoserine mimetics,14-3-3 binding motifs,Forkhead-associated (FHA) domains,14-3-3 Protein Inhibitory Activity,"targets including the tumor suppressor p53, Raf family kinases, FOXO transcription factors, the proapoptotic protein BAD, and Cdc25 phosphatases through these recognition sequences. Upon binding, 14-3-3 acts as an adaptor, leading to changes in enzymatic activity or subcellular localization .These characteristics make the 14-3-3 family an interesting target for cancer therapeutics"
2013,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392204/,Protein,phosphoserine mimetics,14-3-3 binding motifs,WD40,14-3-3 Protein Inhibitory Activity,"targets including the tumor suppressor p53, Raf family kinases, FOXO transcription factors, the proapoptotic protein BAD, and Cdc25 phosphatases through these recognition sequences. Upon binding, 14-3-3 acts as an adaptor, leading to changes in enzymatic activity or subcellular localization .These characteristics make the 14-3-3 family an interesting target for cancer therapeutics"
2013,https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3392204/,Protein,phosphoserine mimetics,14-3-3 binding motifs,LRR domains of F-box protein,14-3-3 Protein Inhibitory Activity,"targets including the tumor suppressor p53, Raf family kinases, FOXO transcription factors, the proapoptotic protein BAD, and Cdc25 phosphatases through these recognition sequences. Upon binding, 14-3-3 acts as an adaptor, leading to changes in enzymatic activity or subcellular localization .These characteristics make the 14-3-3 family an interesting target for cancer therapeutics"
2014,https://doi.org/10.3389/fimmu.2014.00308,Carbohydrate,"natural peptides derived from proteins, such as those from the Mucin 1 cell surface receptor (MUC1), which are considered mimics of carbohydrate antigens like the Gal-epitope",Gal-epitope,carbohydrate-mimetic peptides (CMPs),"inducing immune responses to glycan antigens expressed on cancer cells and pathogens, mediating cognate B and T-cell interactions, and potentially functioning as probes to understand the structural basis for the dual recognition properties of antibodies, lectins, and T cells","inducing immune responses that can inhibit tumor growth in vivo, generating antibodies capable of neutralizing pathogens such as HIV-1, and mediating cytotoxic activity against tumor cells."
2014,https://link.springer.com/chapter/10.1007/7355_2014_50,Carbohydrate,Iminosugar,mannose,swainsonine,"Modulates the action of enzymes involved in carbohydrate synthesis and metabolism, specifically as an inhibitor of α-mannosidase.","1. Potential anti-cancer agent: Inhibits tumor cell growth, reduces metastasis, and enhances cellular immune responses"
2014,https://doi.org/10.4161/hv.34300,Carbohydrate,Carbohydrate Mimetic Peptide (CMP),Lewis Y (LeY) carbohydrate antigens,P10s,Induces anti-tumor antibody response and is hypothesized to interfere with cellular pathways involved in tumor cell survival.,"The P10s vaccine resulted in responses to P10s, with serum and plasma antibodies that were reactive with and cytotoxic to human breast cancer cells in vitro, including a Trastuzumab-resistant cell line. It also suggested sensitization of tumor cells for more efficient killing upon administration of chemotherapy (docetaxel)"
2014,https://doi.org/10.1517/17425247.2014.902048,Carbohydrate,Glycopolymers,"Naturally occurring polysaccharides (e.g., glycosaminoglycans, chondroitin sulfate)",Glycopolymers,"Anticoagulant, anti-inflammatory, anti-tumor properties","Potential applications in treating cardiovascular diseases, inflammatory conditions, and cancer by mimicking biological activities of natural polysaccharides. May also be used as drug delivery systems and protein stabilizers in pharmaceutical formulations."
2014,https://doi.org/10.1021/cr400698c,Protein,peptidomimetic,MLL1,MM-101,treatment of certain forms of leukemia,Potential treatment for certain leukemias by binding to WD40 propeller of MLL1
2014,https://doi.org/10.1021/cr400698c,Protein,peptidomimetic,MLL1,MM-102,treatment of certain forms of leukemia,inhibits cell growth and induces apoptosis in leukemia cells bearing MLL1 fusion proteins
2014,https://doi.org/10.1073/pnas.1402393111,Protein,a helix mimetic,HIF1α,Oxopiperazine helix mimetics (OHMs),modulate the target interaction in cell culture and suppress hypoxia-inducible gene expression,Potential anti-cancer activity by suppressing hypoxia-inducible gene expression
2014,https://doi.org/10.1039/C3BM60293A,Protein,VEGF mimetic peptide,VEGF,QK peptide,retains its bioactivity when tethered and effectively promotes endothelial cell attachment and proliferation,"It enhances the growth of human umbilical vein endothelial cells (HUVECs) when used in soluble form or when conjugated to ELP gels, maintaining a constant concentration for prolonged signaling, potentially promoting angiogenesis in ischemic or wound healing conditions"
2014,https://doi.org/10.1158/1541-7786.MCR-13-0611,Protein,peptidomimetic,α-helix,D2,inhibits androgen-induced multiplication of prostate cancer cells,Inhibits prostate cancer cell growth by blocking AR nuclear translocation
2014,https://doi.org/10.1158/1541-7786.MCR-13-0611,Protein,peptidomimetic,α-helix,anthracene scaffold,induce cell apoptosis,Induces cancer cell apoptosis by inhibiting Bcl-2 family interactions
2015,https://doi.org/10.1002/ejoc.201403186,Carbohydrate,C-Glycosides,D-talose,Aryl C-glycosides,"Enhanced stability against enzymatic degradation
Improved oral bioavailability","Potential anticancer, antioxidant, antiviral, and hypoglycemic effects; May act as enzyme inhibitors for various diseases"
2015,https://doi.org/10.1002/ejoc.201403186,Carbohydrate,C-Glycosides,D-talose.,"Bicyclic 1,2-oxazines","Enhanced stability against enzymatic degradation
Improved oral bioavailability","Potential anticancer, antioxidant, antiviral, and hypoglycemic effects; May act as enzyme inhibitors for various diseases"
2015,https://doi.org/10.1016/j.copbio.2014.11.016,Carbohydrate,Synthetic Receptor,Beta-mannosides,Pyrrolic Tripodal Receptor,Specifically recognizes beta-mannosides.,"Potential for targeted drug delivery, biosensing, and diagnostic applications related to mannoside-mediated processes. May be used to target cancer cells that overexpress mannose receptors or to modulate immune responses."
2015,https://doi.org/10.1021/acs.orglett.5b02223,Carbohydrate,S-linked hexasaccharide,Hexasaccharide subunit of landomycin A,S-linked hexasaccharide of landomycin A,Designed to be resistant to acid-mediated or enzymatic hydrolysis,"The mimetic is associated with antitumor activity against cancer cell lines, as landomycin A possesses a broad spectrum of antitumor activity"
2015,https://doi.org/10.1002/chem.201500831,Carbohydrate,Glycomimetic drug,Sialyl Lewis x (sLe^x),GMI-1271,Specific E-selectin inhibitor,Evaluated in clinical trials in combination with chemotherapy for treating acute myeloid leukemia
2015,https://doi.org/10.1002/chem.201500831,Carbohydrate,Glycan-based therapeutic,Various carbohydrate structures (often mimicking natural glycan epitopes),Multivalent Glycoconjugates,Designed to enhance affinity for protein targets by mimicking the multivalent nature of interactions between lectins and their natural carbohydrate ligands,"Developed to improve the overall affinity of glycan therapeutics, with examples including glycodendrimers and glycoclusters."
2015,https://doi.org/10.1002/chem.201500831,Carbohydrate,Glycolipid mimic,a-GalCer,Synthetic C-glycoside analogues of a-GalCer glycolipid,Stimulates human NKT cells,activity in malaria and melanoma models
2015,https://doi.org/10.1021/jm501440q,Protein,inhibitor,BH3 protein,JY-1-106,indues apoptosis,Potential anti-cancer activity by inducing apoptosis through disruption of Bcl-xL and Mcl-1 interactions with Bak
2015,https://doi.org/10.1038/cdd.2015.50,Protein,inhibitor,BH3 protein,ABT-199/venetoclax,treatment of CLL,Treatment of chronic lymphocytic leukemia (CLL) by selectively inhibiting BCL-2
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylglucosamine,GlcNAz (N-acetylglucosamine azide),Metabolically incorporated into cells for labeling and detection.,Used in glycobiology research to study glycosylation processes in cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylmannosamine,ManNAz (N-acetylmannosamine azide),Metabolically incorporated into cells.,Used in glycobiology research to study glycosylation processes in cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylgalactosamine,GalNAz (N-acetylgalactosamine azide),Metabolically incorporated into cells.,Facilitates the labeling of glycoproteins and tracking of glycosylation
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylmannosamine,ManNAl (N-acetylmannosamine alkyne),Used for metabolic incorporation and subsequent 'click' reactions.,Allows for the study of cell surface glycans and their role in diseases
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylmannosamine,ManNCyoc (N-acetylmannosamine cyano),Metabolically incorporated into cells.,"Used in studies of glycosylation and cellular interactions, impacting diseases processes"
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylmannosamine,ManNMCp (N-acetylmannosamine methylcyclopropene),Metabolically incorporated into cells.,Facilitates the study of glycosylation patterns
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,N-acetylmannosamine,ManNCp (N-acetylmannosamine cyclopropene),Used for metabolic incorporation.,Allows for the tracking of modified glycans in the context of cancer and other diseases
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,Sialic acid,BCNSia (a specific sialic acid mimic),Used in studies of glycosylation.,Helps in understanding the role of sialylation in cellular processes related to cancer and immune responses
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Nucleotide sugar,Xylose,UDP-4-XylAz (uridine diphosphate 4-xylose azide),Used for metabolic incorporation into glycan structures.,Facilitates the study of glycan biosynthesis
2016,https://doi.org/10.1016/j.cbpa.2016.08.027,Carbohydrate,Non-natural sugar,Glucosamine,GlcN-n-Iso ,Used for metabolic incorporation into cellular processes.,"it can be utilized in studies related to glycosylation and may serve as a tool for investigating glycan interactions and modifications in biological systems, particularly within cancer cells."
2016,https://doi.org/10.3389/fbioe.2015.00211,Protein,Stimuli-responsive peptide,β-hairpin,Max3,"potential cancer drug, antimicrobials and wound healing","folding triggered by UV light , changes in pH, electronegative cancer cell membranes"
2016,https://pubmed.ncbi.nlm.nih.gov/27267699/,Protein,small molecule ligand,Nutlins,Mdm2,targets protein-protein interactions,Potential cancer treatment by inhibiting p53-Mdm2 interaction
2016,http://dx.doi.org/10.1016/j.cell.2016.03.045,Protein,styryl- benzyl sulfone,RAS-mimetic,rigosertib,"disrupts RAF activation, and inhibits the RAS-RAF-MEK pathway",Potential cancer treatment by disrupting RAF activation and inhibiting RAS-RAF-MEK pathway
2016,https://pubmed.ncbi.nlm.nih.gov/27915971/,Protein,bivalent mimetic,SMAC mimetic,TL32711 (birinapant),Promotes apoptosis,suppresses cIAP1 and increases apoptosis in peripheral blood mononuclear cells and tumor tissue in some patients.
2016,https://pubmed.ncbi.nlm.nih.gov/27915971/,Protein,monovalent mimetic,SMAC mimetic,LCL161,treatment of solid tumours,Potential treatment for solid tumors by inducing cIAP1 degradation and caspase-3 cleavage
2016,https://pubmed.ncbi.nlm.nih.gov/27915971/,Protein,monovalent mimetic,SMAC mimetic,DEBIO1143/AT-406,treatment of solid tumours,Potential treatment for solid tumors by degrading cIAP1 and increasing cytokine levels
2016,https://pubmed.ncbi.nlm.nih.gov/27194727/,Protein,inhibitor,smac mimetic,birinapant,induces necroptosis and treat acute myeloid leukemia,Caspase inhibitors might sensitize cells to SMAC mimetics by inhibiting caspase-8 and promoting necroptotic cell death
2017,https://doi.org/10.1002/chem.201703129,Carbohydrate,"five-membered heterocycles containing one double bond, 
one oxygen and one phosphorus atom",Furanose carbohydrate,"Oxaphospholenes 
3-4",serve as precursors for furanose carbohydrate mimics,Potential applications in developing anti-cancer and anti-diabetic drugs by mimicking furanose-based enzyme substrates or inhibitors
2017,https://doi.org/10.1039/C7OB00386B,Carbohydrate,Glycolipid mimetics,Monosaccharides,Penaresidins,"Actomyosin ATPase activator, potential biomarker","Cytotoxicity against cancer cell lines, potential biomarker for cervical cancer, antimicrobial activity against Mycobacterium tuberculosis"
2017,https://doi.org/10.1039/C7OB00386B,Carbohydrate,Glycolipid mimetics,Monosaccharides,Penazetidine A,Protein kinase C inhibitor,"Cytotoxicity against human and murine cell lines (A549, HT-29, B16/F10, P388), potential anticancer activity"
2017,https://doi.org/10.1039/C7OB00386B,Carbohydrate,Cyclobutane derivatives,Monosaccharides,Highly-functionalized cyclobutanes,Explored for their potential in medicinal chemistry.,"May improve drug properties such as metabolic stability and conformational restriction, with potential applications in various diseases including cancer, viral infections, and neurodegenerative disorders"
2017,https://doi.org/10.1016/j.carres.2017.03.012,Carbohydrate,Carbasugars,Various sugars,Carbasugars,"Enhanced biostability and inhibition of specific enzymes (e.g., Ser/Thr protein kinase, SGLT2, heparanase)","Potential treatments for cancer, diabetes, and inflammatory diseases due to their increased chemical stability and specific enzyme inhibition"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Carbohydrate,Cyclitol analogue,Rhamnose,2a (n-Pr cyclitol diacetate),Designed to improve bioavailability and inhibit RSK1/2 activity.,"Potential anticancer agent due to improved RSK inhibition, which may suppress tumor growth and metastasis"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Carbohydrate,Cyclitol analogue,Rhamnose,2b (C-3/C-4 bis-carbamate),Aimed at enhancing stability and RSK inhibition.,"Promising anticancer activity through RSK inhibition, potentially effective in treating various types of cancer"
2017,https://doi.org/10.1021/acs.orglett.7b00945,Carbohydrate,Carbasugar analogue,"Sugars in general, particularly rhamnose derivatives.",5a-carbasugar analogues,To explore structure-activity relationships and improve RSK1/2 inhibition.,Part of ongoing research to develop more effective anticancer treatments targeting RSK-mediated pathways
2017,https://doi.org/10.1021/acs.orglett.7b00945,Carbohydrate,Structural modification,Rhamnose (specifically the C-3 and C-4 positions),C-3/C-4-n-Pr-carbamates,To enhance the stability and efficacy of the analogues.,Potential improvement in anticancer activity through more stable and effective RSK inhibition
2017,http://dx.doi.org/10.1016/j.sbi.2016.12.009,Protein,PPI inhibitor,Arg-Gly-Asp acid (RGD),"Cilengitide (Merck-Ser-ono), c(RGDf(NMe)V)",Acts as an inhibitor between the integrins,Potential anti-cancer agent by inhibiting integrin interactions
2017,https://doi.org/10.3390/ph10040078,Protein,heparin mimetic,Heparin,PG454,inhibits heparanase with low anti-coagulant properties,Potential anti-cancer agent by inhibiting heparanase
2017,https://doi.org/10.3390/ph10040078,Protein,heparin mimetic,Heparin,M402,"inhibits epithelial-to-mesenchymal transition, a key step in the progression of tumor cells towards a more invasive phenotype","reduces anticoagulant activity and inhibition of tumor metastasis through the modulation of factors, such as P-selectin, VEGF, and FGFs"
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,affibodies,antibody,Z05416,inhibits heregulin (HRG)-induced cancer cell growth,Potential anti-cancer agents by inhibiting HER3-HRG interaction
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,affibodies,antibody,Z05417,inhibits heregulin (HRG)-induced cancer cell growth,Potential anti-cancer agents by inhibiting HER3-HRG interaction
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,anticalins,NGAL,lipocalin,immunotherapy of cancer and infectious diseases,Potential immunotherapy for cancer and infectious diseases
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,Adnectins,antibody,Ct-322,promotes antitumor activities,Potential anti-cancer agent by inhibiting VEGFR-2
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,Fc small antibody,antibody,HMTI-Fc,recruits the immune cells in antibody-dependent cell-mediated cytotoxicity (ADCC),"inhibits the binding of trastuzumab with HER2-overexpressing SK-BR3 cells, thus shows its potential to treat cancer"
2017,https://doi.org/10.1007/978-1-4939-6857-2_1,Protein,affibody,antibody,99mTc- (mercaptoacetyl-Glu-Glu-Glu) maEEE-ZHER2:342,better tracer for clinical imaging of HER2 overexpression in tumors and metastases,Potential improved diagnosis of HER2-positive tumors and metastases
2017,https://doi.org/10.1016/bs.ircmb.2016.09.004,Protein,Smac mimetic,Smac/DIABLO,BV6,Therapeutically Targets IAP Proteins in Cancer,"mediates cell death depended on a TNFα/TNFR1-stimulated signaling and IRF1 in AML cells, since pharmacological or genetic inhibition of TNFα, TNFR1, or IRF1 rescued cell death upon treatment with Smac mimetic,Potential cancer treatment by targeting IAP proteins"
2017,https://doi.org/10.1016/bs.ircmb.2016.09.004,Protein,Smac mimetic,Smac/DIABLO,IFNα,Therapeutically Targets IAP Proteins in Cancer,"sensitizes cells, including CD34-positive AML stem– progenitor cells, to demethylating drugs such as 5-azacitadine or 5-Aza-2-deoxycytidine (5-Aza),Potential treatment for AML by sensitizing cells to demethylating drugs"
2017,https://doi.org/10.1021/acsbiomaterials.7b00600,Protein,secondary structure,MCP-1 peptide,MCP-1 PAMs,"presence of prostate cancer cells,displayed anticancer efficacy by reducing CCR2 expression.","displayed improved binding and chemoattractant properties to monocytes, which upregulated the inflammatory signaling pathways responsible for monocyte migration , Potential anti-cancer agent for prostate cancer"
2018,https://doi.org/10.1002/ejoc.201701601,Carbohydrate,Glycosidase Inhibitors,Retaining β-glucopyranosides,Cyclophellitol Aziridine (2),Acts as an irreversible covalent inhibitor of retaining β-glucosidases.,"Inhibits enzyme by forming a covalent bond with the active site, rendering it inactive."
2018,https://doi.org/10.1002/ejoc.201701601,Carbohydrate,Glycosidase Inhibitors,α- and β-galactopyranose configured analogues,Carba-Cyclophellitol Derivatives,Competitive inhibitors of retaining β-galactosidases.,"Bind to the enzyme's active site, competitively inhibiting substrate binding and enzymatic activity."
2018,https://doi.org/10.1016/j.aca.2018.08.025,Carbohydrate,Monosaccharide (Galactose),Galactose,Carbohydrate-mimetic peptide (YYYYC),"Mimics galactose residues to bind galactose-recognizing proteins such as SBA, facilitating detection of target proteins and cells with galactose-terminal carbohydrate chains.","Acts as an electron-transfer sensor in electrochemical assays; interacts specifically with galactose-binding proteins and receptors on cells, enabling label-free detection of cancer cells and proteins related to galactose-binding."
2018,https://doi.org/10.1016/j.aca.2018.08.026,Carbohydrate,"Monosaccharides (Galactose, N-acetylgalactosamine)",N-acetylgalactosamine and galactose,Peptides with YXY sequences (general class),"Serve as carbohydrate-mimetic units capable of binding to carbohydrate-binding proteins (lectins and galectins), enabling the recognition of specific glycan structures on cell surfaces or glycoproteins, especially those altered in cancer.","Function as probes in electrochemical sensing systems; facilitate interactions with target proteins and cells that display specific carbohydrate epitopes, aiding in disease diagnostics like cancer cell detection"
2018,https://doi.org/10.1016/j.aca.2017.11.048,Carbohydrate,"Monosaccharide (specifically, a hexose).",Methyl α-D-mannopyranoside,DVFYPYPYASGS,"Interacts with ConA, mimicking the binding of carbohydrate",Binding constant reported to be 2.2 × 10⁴ L/mol; suppresses ConA-induced T-cell proliferation
2018,https://doi.org/10.1016/j.aca.2017.11.049,Carbohydrate,tumor-associated glycoproteins or glycolipids,Not explicitly mentioned,IFLLWQR,Targets properties of annexin for tumor targeting,Demonstrates specific tumor-targeting activity and serves as a vehicle for anti-cancer drugs
2018,https://doi.org/10.1016/j.aca.2017.11.050,Carbohydrate,galactose,Not explicitly mentioned,YYYY-C and YYYYY-C,Functions as an electron-transfer agent and interacts with carbohydrate-binding proteins,Demonstrates electroactivity in the context of molecular recognition
2018,https://doi.org/10.1038/s41467-017-02693-9,Protein,mimetic inhibitor.,BCL-2,ABT-199 (Venetoclax),"Inhibits the anti-apoptotic function of BCL-2, promoting apoptosis in cancer cells.","Selectively binds to BCL-2, preventing it from sequestering pro-apoptotic proteins."
2018,https://doi.org/10.1038/s41467-017-02693-9,Protein,mimetic inhibitor.,BCL-2 and BCL-XL,ABT-263 (Navitoclax),"Induces apoptosis by inhibiting BCL-2 and BCL-XL, which are crucial for cell survival.",Disrupts the interaction between pro-apoptotic and anti-apoptotic BCL-2 family proteins.
2018,https://doi.org/10.1038/s41467-017-02693-9,Protein,inhibitor.,MCL1,S63845,"Specifically targets and inhibits MCL1, leading to apoptosis in MCL1-dependent cancer cells.","Blocks the anti-apoptotic function of MCL1, enhancing the effectiveness of other therapies."
2018,https://doi.org/10.1038/s41467-017-02693-9,Protein,Deubiquitinase inhibitor.,USP13 (indirectly),Spautin-1,"Inhibits USP13, leading to decreased MCL1 stability and increased sensitivity to BH3 mimetics.",Promotes degradation of MCL1 through the proteasomal pathway.
2018,https://doi.org/10.1186/s12868-018-0482-4,Protein,Pharmacological agent,mTOR inhibition,Rapamycin,"Rapamycin is a well-known inhibitor of the mammalian target of rapamycin (mTOR), which regulates cell growth, metabolism, and survival.","It increases cell viability during CoCl2 exposure, reduces activation of caspases-9 and -3, and promotes autophagy by increasing Beclin-1 and converting LC3-I to LC3-II."
2018,https://doi.org/10.1186/s12868-018-0482-4,Protein,Not Specified Explicitly,Anti-apoptotic protein,Bcl-2 (B cell lymphoma-2),"Bcl-2 helps prevent apoptosis by inhibiting the release of cytochrome c from mitochondria, thus blocking the intrinsic apoptotic pathway.","Its expression increases with rapamycin treatment, contributing to reduced oxidative stress and promoting cell survival."
2018,https://doi.org/10.1186/s12868-018-0482-4,Protein,Not Specified Explicitly,Pro-apoptotic protein,Bax (Bcl-2 associated X protein),Bax promotes apoptosis by facilitating mitochondrial outer membrane permeability (MOMP) and triggering the release of pro-apoptotic factors.,"The expression of Bax decreases with rapamycin treatment, which helps to favor cell survival by lowering the Bax/Bcl-2 ratio."
2018,https://doi.org/10.1080/21691401.2018.1489824,Protein,Not Specified Explicitly,NK-EM,Perforin,"Perforin is crucial for the cytotoxic activity of NK cells. It forms pores in the target cell membrane, facilitating the entry of granzymes.","Triggers the intrinsic apoptotic pathway by releasing cytochrome-c from mitochondria, leading to cell death."
2018,https://doi.org/10.1080/21691401.2018.1489824,Protein,Not Specified Explicitly,NK-EM,Granzyme B,Granzyme B is a serine protease that enters target cells through the pores created by perforin and initiates apoptosis.,"Activates caspases, which are essential for the apoptotic process, leading to cell death."
2018,https://doi.org/10.1080/21691401.2018.1489824,Protein,Not Specified Explicitly,NK-EM,Fas Ligand (FasL),"FasL binds to the Fas receptor on target cells, triggering the extrinsic apoptotic pathway.","Activates caspase-8 and caspase-3, leading to apoptosis of the target cell."
2018,https://doi.org/10.1080/21691401.2018.1489824,Protein,Not Specified Explicitly,Cleaved caspase-3 in NK-EM,Caspase-3,Caspase-3 is an executioner caspase that plays a pivotal role in the apoptosis process.,"Cleaved caspase-3 indicates the activation of the apoptotic pathway, leading to cell death"
2018,https://doi.org/10.1080/21691401.2018.1489824,Protein,Not Specified Explicitly,Cleaved PARP in NK-EM,Cleaved PARP (Poly (ADP-ribose) polymerase),PARP is involved in DNA repair; its cleavage is a marker of apoptosis.,The presence of cleaved PARP indicates that the cell is undergoing apoptosis.
2018,https://doi.org/10.1101/312447,Protein,Smac mimetic,Active N-terminal tetrapeptide of SMAC,AZD5582,", it promotes apoptosis by inhibiting IAPs.",": AZD5582 has been shown to potently induce degradation of cIAP1 and cIAP2, leading to activation of the ncNFκB pathway and increased expression of HIV RNA in resting CD4+ T cells."
2018,https://doi.org/10.3389/fphar.2018.01298,Protein,Smac mimetic,SMAC (Second Mitochondria-derived Activator of Caspases),APG-1387,"APG-1387 acts as an inhibitor of apoptosis proteins (IAPs) by mimicking the binding interaction between IAPs and SMAC. This leads to the activation of caspases, which are crucial for the apoptotic process.","Induces apoptosis in hepatocellular carcinoma (HCC) cells, particularly when combined with cytokines like TNF-α or TRAIL."
2019,https://www.tandfonline.com/doi/full/10.2147/IJN.S213455#d1e223,Carbohydrate,peptides,Annexin A1,motif IF-7 (IF-7-MNC),"To deliver the chemotherapeutics through the nanoparticles, the delivery system should accumulate at the tumor site first and then penetrate through the interstitium into the interior",enhancing tumor targeting and promoting the penetration of the drug delivery system into tumor tissues
2019,https://doi.org/10.3390/ijms20235835,Protein,affinity proteins ;targeting receptors,staphylococcal protein A.,Affibody molecules,designed to target the HER2 receptor in breast cancer cells.,"have rapid clearance, high tissue penetration, and the ability to bind to a unique epitope of the HER2 receptor"
2019,https://doi.org/10.1073/pnas.1819663116,Protein,Not Specified Explicitly,B Cell Lymphoma 9 (BCL9),BCL9 peptide 1,"disrupt the β-catenin/BCL9 PPI but is less potent compared to the sulfono-γ-AApeptides, with higher K_i and IC_50 values","designed to structurally and functionally mimic the α-helical HD2 domain of BCL9, effectively inhibiting cancer-related signaling pathways associated with β-catenin"
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,ABT-737,Inhibits anti-apoptotic proteins to promote apoptosis.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,ABT-263 (Navitoclax),Induces apoptosis by inhibiting anti-apoptotic proteins.,Induces apoptosis by inhibiting anti-apoptotic proteins.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-2/BCL-XL inhibitor,BCL-2 and BCL-XL,AZD4320,Antagonizes the function of anti-apoptotic proteins.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-2 inhibitor,BCL-2,ABT-199 (Venetoclax),Selectively inhibits BCL-2 to promote apoptosis in BCL-2-dependent cells.,"Effective in low to mid-nanomolar range, validated as a BH3 mimetic."
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-XL inhibitor,BCL-XL,WEHI-539,Selectively inhibits BCL-XL to induce apoptosis.,Strong selective release of cytochrome c from BCL-XL-dependent mitochondria.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-XL inhibitor,BCL-XL,A-1155463,Inhibits BCL-XL to promote apoptosis.,Demonstrated strong selective activity in BCL-XL-dependent cells.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,BCL-XL inhibitor,BCL-XL,A-1331852,Antagonizes BCL-XL to induce cell death.,Most potent BCL-XL inhibitor among tested compounds.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,MCL-1 inhibitor,MCL-1,A-1210477,Most potent BCL-XL inhibitor among tested compounds.,Induces cytochrome c release from MCL-1-dependent mitochondria.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,MCL-1 inhibitor,MCL-1,S63845,Induces cytochrome c release from MCL-1-dependent mitochondria.,Effective in inducing cytochrome c release from MCL-1-dependent cells.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,MCL-1 inhibitor,MCL-1,AMG176,Selectively inhibits MCL-1 to induce apoptosis.,Validated as a true BH3 mimetic with effective mitochondrial activity.
2019,https://doi.org/10.1038/s41418-019-0391-9,Protein,MCL-1 inhibitor,MCL-1,AZD5991,Inhibits MCL-1 to promote apoptosis.,Induces cytochrome c release from MCL-1-dependent mitochondria.
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Protein,Acetyltransferase inhibitor,EP300 (E1A-Associated Protein p300),EP300 Inhibitors,Inhibition of acetyltransferase activity.,"Promotes autophagy through deacetylation of proteins like PI3K3 and BECN1, enhancing their interaction with pro-autophagic complexes."
2019,https://doi.org/10.1016/j.cmet.2019.01.018,Protein,Acetyltransferase inhibitor,KATs (Lysine Acetyltransferases),KAT Inhibitors,Inhibition of acetylation processes.,Induces autophagy by reducing acetylation levels of key proteins.
2019,https://doi.org/10.1093/rb/rbz027,Protein,Not Specified Explicitly,Vascular Endothelial Growth Factor (VEGF),KLT (KLTWQELYQLKYKGI),": The KLT peptide is designed to activate VEGF receptors, promoting angiogenesis, which is the formation of new blood vessels.","It has been shown to promote endothelial cell (EC) growth, migration, and tubulogenesis, which are critical processes in angiogenesis"
2019,https://doi.org/10.1002/adfm.202402521,Protein,Not Specified Explicitly,Apoptotic Cells,Phosphatidylserine-Incorporated Exosome Mimetics (PS-EMs),"PS serves as an ""eat-me"" signal that is recognized by macrophages, facilitating phagocytosis of apoptotic cells. This mimetic aims to exploit the immunosuppressive properties of PS to enhance therapeutic effects in osteoporotic conditions.","The PS-EMs are designed to enhance the affinity for osteoclast precursors, thereby promoting targeted delivery and potentially modulating bone resorption."
2019,https://doi.org/10.1186/s12885-019-6103-5,Protein,Smac mimetic,Smac,LCL161,"LCL161 acts as an inhibitor of IAP (Inhibitor of Apoptosis) proteins, particularly targeting XIAP (X-linked Inhibitor of Apoptosis Protein), cIAP1, and cIAP2.","It promotes cell death by relieving the inhibition of caspases (caspase-3, -7, and -9) that are normally blocked by XIAP. This leads to the activation of the apoptotic pathway, facilitating the death of cancer cells, particularly in the context of osteosarcoma when combined with TNFα"
2019,https://doi.org/10.1186/s12885-019-6103-5,Protein,smac mimetic,Smac,GDC-0152,"Similar to LCL161, GDC-0152 inhibits IAP proteins, including XIAP, cIAP1, and cIAP2, thereby promoting apoptosis in cancer cells","GDC-0152 has been shown to sensitize osteosarcoma cells to TNFα-induced cell death, particularly when TNFα is provided exogenously, as these cells do not produce it autocrinely"
2019,https://doi.org/10.1016/j.celrep.2020.108286,Protein,Not Specified Explicitly,BCL-2,Obatoclax,Acts as a BH3 mimetic to promote apoptosis in cancer cells.,Acts as a BH3 mimetic to promote apoptosis in cancer cells.
2019,https://doi.org/10.1016/j.celrep.2020.108286,Protein,Not Specified Explicitly,BMI1,PTC028,"Inhibits BMI1, leading to decreased self-renewal and induction of senescence in tumor cells.","It drives cancer cells into a senescent state, which can be beneficial in controlling tumor growth."
2019,https://doi.org/10.1021/acs.bioconjchem.9b00259,Protein,Cell-adhesion peptide.,Integrin proteins,Integrin-binding Cyclic RGDfK Peptide,"Used to create multivalent presentations on DNA scaffolds, effectively inhibiting melanoma cells that overexpress integrins. The study found that a construct with 15 peptides maximized efficiency in binding, demonstrating the importance of spatial arrangement in enhancing activity.","The integrin-binding cyclic RGDfK peptide specifically targets αvβ3 integrin with high affinity, inhibiting integrin-mediated signaling pathways critical for angiogenesis, tumor growth, and metastasis"
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,GDC-0152,"Inhibits IAPs, promoting apoptosis in cancer cells.",Demonstrated anti-cancer effects in preclinical studies.
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,CUDC-427 (GDC-0917),Targets IAPs to enhance the efficacy of chemotherapy.,Shown to sensitize cancer cells to treatment.
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,Debio 1143 (AT-406),"inhibits IAPs, facilitating apoptosis.",Exhibited potential in various cancer types.
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,LCL161,Disrupts IAP function to promote cell death.,Effective in preclinical cancer models.
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,BI 891065 (BI5),Higher selectivity towards cIAP1 and cIAP2 compared to XIAP.,Modest efficacy in bladder and breast cancer cell lines.
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,Birinapant (TL32711),Binds to IAPs to promote apoptosis.,Undergoing clinical trials for various cancers
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,APG-1387,Inhibits IAPs to induce cancer cell death.,Inhibits IAPs
2020,https://doi.org/10.3390/cells9020406,Protein,Not Specified Explicitly,Smac,HGS1029 (AEG40826),Targets IAPs to enhance apoptosis.,Targets IAPs
2020,https://doi.org/10.2147/IJN.S253576,Protein,Not Specified Explicitly,Integrins,RGD (Arg-Gly-Asp) Mimetic Peptide,"Promotes cell attachment and survival, particularly for dental pulp stem cells (DPSCs).",Enhances the proliferation and differentiation of DPSCs by facilitating their adhesion to the extracellular matrix (ECM).
2021,https://doi.org/10.1038/s41467-021-23985-1,Protein,Amyloid inhibitor,mutant p53 protein in cancer cells.,ADH-6,targets and dissociates mutant p53 aggregates in human cancer cells.,"It restores p53's transcriptional activity, leading to cell cycle arrest and apoptosis"
2021,https://doi.org/10.1186/s13046-021-02157-5,Protein,Small molecule inhibitor.,"Bim, Bad, and Bid (pro-apoptotic BH3-only proteins)",ABT-737,"Disrupts the interaction between pro-apoptotic and anti-apoptotic Bcl-2 proteins,",promotes apoptosis in cancer cells.
2021,https://doi.org/10.1186/s13046-021-02157-5,Protein,Small molecule inhibitor.,Bim and Bad,Navitoclax (ABT-263),"Induces apoptosis by inhibiting Bcl-2, Bcl-xL, and Bcl-w",activation of BAX and BAK.
2021,https://doi.org/10.1186/s13046-021-02157-5,Protein,Engineered peptide.,Bcl-xL,DT2216,"Designed to degrade Bcl-xL, reducing its off-target effects",enhancing apoptosis in cancer cells.
2021,https://doi.org/10.1186/s13046-021-02157-5,Protein,nanostructured peptide,BIM (a pro-apoptotic BH3-only protein),BIM BH3-mimetic peptide amphiphile,Facilitates the uptake of the mimetic,trigger cell death in cancer cells like HeLa and MEF.
2021,https://doi.org/10.3390/molecules26102937,Protein,Anticancer agents,Heat Shock Protein 90 (Hsp90),Sansalvamide A (San A) Derivatives,Inhibition of protein folding and stabilization.,"maintain cytotoxicity while incorporating triazoles, oxazoles, and thiazoles as amide bond surrogates."
2021,https://doi.org/10.3390/molecules26102937,Protein,Not Specified Explicitly,Tumor-associated αvβ3-integrin receptors,GlycoRGD Peptide,Selective binding to integrin receptors involved in cell adhesion and migration.,"The amide bond is replaced by a triazole without losing biological activity, enhancing stability and bioavailability."
2021,https://doi.org/10.3390/molecules26102937,Protein,Antimetastatic agents,Fascin,Migrastatin Analogues,Inhibition of cell motility.,Triazole analogues of migrastatin showed significant effects in reducing migration capacity in MDA-MB-361 cell lines.
2021,https://doi.org/10.3390/app11010335,Protein,Monovalent Smac mimetic,Smac/DIABLO,LCL161,"Inhibits IAPs, promoting apoptosis in cancer cells.",Induces caspase-dependent apoptosis and can also affect the non-canonical NF-kB signaling pathway.
2021,https://doi.org/10.3390/app11010335,Protein,Bivalent Smac mimetic,Smac/DIABLO,Birinapant (TL32711),"Targets IAPs, particularly cIAP1 and cIAP2, to induce apoptosis.",Demonstrated to induce apoptosis and has been studied for its effectiveness in various cancers.
2021,https://doi.org/10.3390/app11010335,Protein,Monovalent Smac mimetic,Smac/DIABLO,GDC-0152,"Acts as a pan-IAP inhibitor, affecting XIAP, cIAP1, and cIAP2.",Induces apoptosis and has shown potential in combination therapies to enhance anti-cancer effects.
2021,https://doi.org/10.3390/app11010335,Protein,Monovalent Smac mimetic,Smac/DIABLO,AT-406 (Debio1143),"Specifically targets cIAP1 and cIAP2, similar to birinapant.",Induces apoptosis and has been evaluated in clinical settings.
2021,https://doi.org/10.3390/app11010335,Protein,Monovalent Smac mimetic,Smac/DIABLO,GDC-0917 (CUDC-427),"Inhibits IAPs, promoting apoptosis.",Evaluated for its anti-cancer potency in preclinical studies.
2021,https://doi.org/10.3390/app11010335,Protein,Bivalent Smac mimetic,Smac/DIABLO,BV6,A bivalent compound that inhibits IAPs.,Shown to suppress cancer cell progression and induce apoptosis in combination therapies.
2021,https://doi.org/10.1021/acs.analchem.1c02109,Protein,Not Specified Explicitly,Mycophenolic Acid (MPA),A2 (cyclic peptide mimetic),"The A2 peptide mimetic is designed to bind to the same antibody paratope as MPA, allowing it to compete with the actual drug in immunoassays. This mimetic is crucial for the development of sensitive detection methods for MPA in clinical samples.",The A2 mimetic demonstrated high selectivity for the recombinant MPA antibody fragment and was effective in competitive phage-based ELISA assays. It was further characterized by its ability to recognize the anti-MPA antibody and compete with free MPA at nanomolar levels
2022,https://doi.org/10.1039/D2CS00470D,Carbohydrate,Carbohydrate Mimetic Peptides (CMPs),Glycan,Glycan-mimetic peptide mimotopes,The regulation of glycan (carbohydrate)–protein interactions is needed to develop therapeutic strategies for glycan-related diseases,"modulate immune responses or inhibit glycan–protein interactions, serving as high-affinity ligands for lectins, inducing anti-glycan antibodies, or acting as vaccine candidates against pathogens and tumors"
2022,https://doi.org/10.1016/j.carres.2022.108697,Carbohydrate,synthetic polysaccharide mimetics,"Glycolipid biosurfactants (C14,C16,C18 terminal chain lengths)",Enantiopure poly-amido-saccharides (PASs),"These amphiphilic polymers are water soluble, adopt a helical secondary structure, decompose at temperatures greater than 240 °C, are non-cytotoxic, and self-assemble into nanostructures.","binding to carbohydrate-recognizing proteins (like lectins) and can act as highly effective protein stabilizers, offering enhanced stability and precise structural control compared to natural polysaccharides"
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Tumor suppressor mimetic.,p53,p53-derived peptides,Inhibits MDM2 interaction.,"Reactivates p53, promoting apoptosis in cancer cells."
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Oncogene inhibitor.,MDM2,MDM2 inhibitors,Inhibits p53 degradation.,"Restores p53 activity, leading to tumor suppression."
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Oncogene mimetic.,BCL9,BCL9-derived peptides,Inhibits β-catenin interaction.,"Modulates Wnt signaling pathway, affecting cell proliferation."
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Oncogene inhibitor.,c-Myc,c-Myc inhibitors,Disrupts c-Myc/Max dimerization.,Inhibits transcription of target genes involved in cell growth.
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Apoptosis-inducing mimetic.,Fas Ligand (FasL),FasL-derived peptides,Induces apoptosis.,Triggers cell death in cancer cells.
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Tumor suppressor mimetic.,TGF-β inhibitors,Transforming Growth Factor Beta (TGF-β),Inhibits TGF-β signaling.,Reduces tumor progression and metastasis.
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Cell adhesion mimetic.,Integrins,Integrin-derived peptides,Modulates cell adhesion.,Affects tumor cell migration and invasion.
2022,https://doi.org/10.1016/j.addr.2021.114044,Protein,Chemokine receptor inhibitor.,CXCR4,CXCR4 antagonists,Inhibits chemokine signaling.,Reduces metastasis and tumor growth.
2022,https://doi.org/10.1021/acscentsci.1c01293,Protein,Not Specified Explicitly,Heparan sulfate (HS),Pixatimod (PG545),"Acts as a coreceptor for the SARS-CoV-2 spike protein, facilitating viral entry into host cells by interacting with the ACE2 receptor.
Disrupts the interaction between the spike protein and ACE2, thereby inhibiting viral infection.","Pixatimod binds to the receptor binding domain (RBD) of the SARS-CoV-2 spike protein, destabilizing it and preventing its binding to ACE2.
Demonstrated potent inhibition of SARS-CoV-2 infection in various cell types, including monkey Vero E6 cells and human bronchial epithelial cells, at therapeutically safe concentrations.
Retains effectiveness against multiple variants of concern (VOC) such as Alpha, Beta, Delta, and Omicron, indicating broad antiviral activity."
2023,https://doi.org/10.1016/j.bioactmat.2022.05.029,Protein,Cell adhesion peptide,Integrin-binding sites found in various extracellular matrix proteins.,RGD-FITC Peptide,Promotes cell adhesion and migration.,Used to validate the thiol-ene reaction on the fibrous scaffolds.